Associate Scientist, Viral Delivery Technologies
Regeneron Pharmaceuticals
Summary
At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking an Associate Scientist to join our Viral Delivery Technologies group, supporting the development and implementation of an antibody-retargeted adeno-associated virus (AAV) delivery platform. In this role, you will support the production and screening of antibody-retargeted AAV libraries, helping to expand the company's gene therapy delivery portfolio while collaborating with the bioinformatics team and other cross-functional groups.
Job description
Discover your role
- Execute rAAV production workflows and characterize production runs
- Perform basic molecular biology and protein analysis techniques (e.g., cloning, SDS-PAGE, Western blotting, ELISA, DNA extractions, PCR, qPCR, protein chromatography)
- Work closely with the bioinformatics team to organize data across screens
- Optimize AAV production protocols to enhance efficiency and yield
- Collaborate with cross-functional teams to coordinate and execute planned productions and screens
- Participate in team meetings and prepare regular presentations for departmental meetings
- Thrive in an innovation-driven, highly collaborative, fast-paced environment
- Work rigorously with keen attention to detail while balancing multiple projects
This role requires
- B.A./B.S. with 2+ years of relevant industry or academic experience, or M.S. in cell biology, molecular biology, biochemistry, bioengineering, antibody science, or a related field with 0-2 years of relevant experience
- Experience with mammalian cell culture
- Experience with virus or protein production and purification
- Familiarity with molecular biology and protein characterization techniques
- Experience maintaining accurate, up-to-date electronic lab records
- Preferred: familiarity with lab automation, key antibody properties, viral vector production, and relevant research software (e.g., Microsoft Office, GraphPad Prism, Benchling, MacVector)
Requirements
- B.A./B.S. with 2+ years of relevant industry or academic experience, or M.S. in cell biology, molecular biology, biochemistry, bioengineering, antibody science, or a related field with 0-2 years of relevant experience
- Experience with mammalian cell culture
- Experience with virus or protein production and purification
- Familiarity with molecular biology and protein characterization techniques
- Experience maintaining accurate, up-to-date electronic lab records
- Preferred: familiarity with lab automation, key antibody properties, viral vector production, and relevant research software (e.g., Microsoft Office, GraphPad Prism, Benchling, MacVector)
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Medical, Dental & Vision
- Life and disability insurance
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.